| Market Capitalization (Millions $) |
1,891 |
| Shares
Outstanding (Millions) |
66 |
| Employees |
60 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-149 |
| Cash Flow (TTM) (Millions $) |
-14 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Tyra Biosciences Inc. is a biotechnology company that specializes in discovering and developing a range of cancer therapies. The company was founded in 2016 and is headquartered in Boston, Massachusetts.
Tyra Biosciences is focused on identifying and developing small molecule therapies that target specific oncogenic signaling pathways. The company has a team of experienced scientists and researchers who are dedicated to advancing the understanding of cancer biology and developing new treatments.
The company's lead product candidate is TYRA-101, which is a small molecule inhibitor of the Met receptor. Met is a protein that plays a critical role in promoting cancer growth and metastasis. TYRA-101 is designed to block Met signaling, which may lead to the inhibition of tumor growth and the suppression of metastases.
In addition to TYRA-101, the company is also developing a pipeline of other small molecule inhibitors that target various pathways involved in cancer progression. These include inhibitors of the EGFR, PDGFR, and VEGFR signaling pathways, which are implicated in several types of cancer.
Tyra Biosciences is committed to advancing the understanding of cancer biology and developing innovative therapies that can improve the lives of patients with cancer. The company has built a strong scientific foundation and is dedicated to bringing new treatments to patients as quickly as possible.
Company Address: 2656 State Street Carlsbad 92008 CA
Company Phone Number: 728-4760 Stock Exchange / Ticker: NASDAQ TYRA
|
12.24% 